We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Rules Out Future Dementia Risk

By LabMedica International staff writers
Posted on 07 Apr 2025

Previous studies have suggested that specific biomarkers, such as tau217, Neurofilament Light (NfL), and Glial Fibrillary Acidic Protein (GFAP), may be valuable for early dementia diagnosis. More...

However, most of these studies have involved individuals who sought medical care due to cognitive symptoms, such as memory difficulties. A larger, community-based study was needed to assess the predictive power of these biomarkers in the general population. Now, a new study published in Nature Medicine has explored the potential of these biomarkers to predict dementia, including Alzheimer's disease, up to ten years before an official diagnosis in cognitively healthy older adults living in the community.

This study, led by researchers at Karolinska Institutet (Stockholm, Sweden) and their collaborators, analyzed blood biomarkers in over 2,100 adults aged 60 and above, who were monitored over a period to track the development of dementia. Ten years later, 17% of participants had been diagnosed with dementia. The biomarkers tested in this study were found to be up to 83% accurate. However, the researchers observed that these biomarkers had low positive predictive values, meaning that elevated levels of the biomarkers alone could not reliably predict who would develop dementia in the next decade. As a result, the researchers recommend against using these biomarkers as widespread screening tools in the general population at this time. The study also suggested that combining the three most significant biomarkers—p-tau217 with NfL or GFAP—could enhance predictive accuracy.

“Our findings imply that if an individual has low levels of these biomarkers, their risk of developing dementia over the next decade is minimal," said Davide Vetrano, associate professor at the same department and the study's senior author. "This information could offer reassurance to individuals worried about their cognitive health, as it potentially rules out the future development of dementia. These biomarkers are promising, but they are currently not suitable as standalone screening tests to identify dementia risk in the general population.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Portable POCT Blood Gas Analyzer
BD100
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.